Abstracts tagged "pregnancy"

Abstract Number: 1003 • ACR Convergence 2023
A Multidisciplinary Obstetric-Medicine/Rheumatology Specialty Clinic in the United States: A Five Year Analysis
Griffin Reed¹, Joyce Mathew¹, Kelsey Rigby², Mery Deeb³, Elena Cravens¹, Anthony Reginato⁴, Gofran Tarabulsi⁵ and Joanne Cunha⁶, ¹Brown University, Providence, RI, ²Dartmouth Hitchcock Medical Center, Falmouth, MA, ³Brown University, Warwick, RI, ⁴The Warren Alpert Medical School of Brown University, Providence, RI, ⁵Women and Infants Hospital, The Warren Alpert Medical School of Brown University, Providence, RI, ⁶The Warren Alpert Medical School of Brown University, Riverside, RI
Background/Purpose: Rheumatic disorders frequently affect women of childbearing age. These diseases and medications used to treat them can have adverse effects on fertility and fetuses.…
Abstract Number: 1682 • ACR Convergence 2023
Prospective Evaluation of Anti-SSA/Ro Pregnancies Supports the Utility of High Titer Antibodies and Fetal Home Monitoring for the Detection of Fetal Atrioventricular Block
Bettina Cuneo¹, Mala Masson², Colin Phoon³, Ashley Roman³, Peter Izmirly⁴, Amit Saxena⁵, Michael Belmont⁶, Christina Penfield³, Young Mi Lee³, Julie Nusbaum⁷, Ruben Acherman⁸, Elena Sinkovskaya⁹, Alfred Abuhamad¹⁰, Majd Makhoul¹¹, Gary Satou¹², Whitnee Hogan¹³, Nelangi Pinto¹³, Anita Moon-Grady¹⁴, Lisa Howley¹⁵, Mary Donofrio¹⁶, Anita Krishnan¹⁶, Homa Ahmadzia¹⁷, Stephanie Levasseur¹⁸, Erin Paul¹⁹, Sonal Owens²⁰, Kristopher Cumberback²¹, Jyothi Matta²², Gary Joffe²³, Christopher Lindblade²⁴, Andrew Rubenstein²⁵, Caitlin Haxel²⁶, Katherine Kohari²⁷, Joshua Copel²⁷, James Strainic²⁸, Tam Doan²⁹, Karla Bermudez-Wagner²⁹, Shreya Sheth²⁹, Stacy Killen³⁰, Theresa Tacy³¹, Michelle Kaplinski³¹, Lisa Hornberger³², Nicola Fraser³, Robert Clancy³ and Jill Buyon³³, ¹University of Colorado, Denver, Denver, CO, ²New York University, New York, NY, ³NYU Grossman School of Medicine, New York, NY, ⁴New York University School of Medicine, New York, NY, ⁵NYU Langone, New York, NY, ⁶New York University Langone Medical Center, New York, NY, ⁷NYU Long Island School of Medicine, Mineola, NY, ⁸Children's Heart Center, Las Vegas, NV, ⁹East Virginia Medical School, East Virginia Medical School, VA, ¹⁰East Virginia Medical School, Norfolk, VA, ¹¹Atrium Health Levine Children's Hospital, Charlotte, NC, ¹²University of California Los Angeles, Los Angeles, CA, ¹³University of Utah, Salt Lake City, UT, ¹⁴University of California San Francisco, San Francisco, CA, ¹⁵Midwest Fetal Care Center, Children's Minnesota/Allina Health, Minneapolis, MN, ¹⁶Children's National Hospital, Washington, DC, ¹⁷George Washington University, Washington, DC, ¹⁸Columbia University, New York, NY, ¹⁹Mount Sinai, New York, NY, ²⁰University of Michigan, Ann Arbor, MI, ²¹University of Kentucky, Lexington, KY, ²²University of Louisville, Louisville, KY, ²³Perinatal Associates of New Mexico, Albuquerque, NM, ²⁴Phoenix Children's Hospital, Phoenix, AZ, ²⁵Dignity Health, Phoenix, AZ, ²⁶University of Vermont Children's Hospital, Burlington, VT, ²⁷Yale University, New Haven, CT, ²⁸UH Rainbow Babies, Cleveland, OH, ²⁹Baylor School of Medicine, Houston, TX, ³⁰Vanderbilt University, Nashville, TN, ³¹Stanford University, Stanford, CA, ³²Stollery Children's Hospital, Edmonton, AB, Canada, ³³Department of Medicine, NYU Grossman School of Medicine, New York, NY
Background/Purpose: The management of fetuses exposed to maternal anti-SSA/Ro autoantibodies is challenging as the clinician weighs the rarity of fetal atrioventricular block (AVB) against the…
Abstract Number: 0467 • ACR Convergence 2023
Cardiovascular Events During Pregnancy: Implications for Adverse Pregnancy Outcomes in Individuals with Autoimmune Rheumatic Diseases and Antiphospholipid Syndrome
Rashmi Dhital, Rebecca Baer and Christina Chambers, University of California San Diego, La Jolla, CA
Background/Purpose: Autoimmune rheumatic diseases (ARD) and antiphospholipid syndrome (APS) are autoimmune conditions with increased risks of cardiovascular complications as well as negative pregnancy consequences. We…
Abstract Number: 1345 • ACR Convergence 2023
Maternal and Infant Outcomes Following Abatacept Exposure During Pregnancy
Michelle Ann Caesar, Diana Johnson, Kenneth Lyons Jones and Christina Chambers, University of California San Diego, La Jolla, CA
Background/Purpose: Abatacept is approved for the treatment of moderate to severe rheumatoid arthritis (RA) and psoriatic arthritis. However, there are limited data on the safety…
Abstract Number: 1683 • ACR Convergence 2023
Moving the ACR’s Reproductive Health Guidelines into Practice: Assessment of a Novel Reproductive Rheumatology ECHO
Megan Clowse¹, Teresa Swezey², Jerome (Jeff) Federspiel², Catherine Sims², Amanda Snyderman², Amy Corneli², Sarahn Wheeler² and JoAnn Zell³, ¹Duke University, Chapel Hill, NC, ²Duke University School of Medicine, Durham, NC, ³University of Colorado Anschutz Medical Campus, Denver, CO
Background/Purpose: Project ECHO™ in an education model that links experts with community providers through a series of video teleconferences. Each conference involves a brief didactic…
Abstract Number: 0468 • ACR Convergence 2023
Patients with Autoimmune Skin Diseases Are at Increased Risk of Adverse Pregnancy Outcomes
Heejo Keum¹, Bonnie Bermas², Shivani Patel¹, Benjamin Chong¹ and Heidi Jacobe¹, ¹University of Texas Southwestern Medical Center, Dallas, TX, ²UT Southwestern, Dallas, TX
Background/Purpose: Increased rates of adverse pregnancy outcomes (APOs) have been reported in association with rheumatologic diseases such as systemic lupus erythematosus (SLE), dermatomyositis (DM), and…
Abstract Number: 1347 • ACR Convergence 2023
Continuing Biologic DMARDs During Pregnancy in Women with Rheumatic Disease Was Not Associated with Increased Unfavorable Pregnancy Outcomes, Serious Infections, and Adverse Effects of Vaccination
Hiromi Shimada¹, Risa Wakiya², Shusaku Nakashima², Taichi Miyagi³, Yusuke Ushio⁴, Koichi Sugihara⁵, Rina Mino⁶, Mao Mizusaki², Kanako Chujo⁷, Ryoko Kagawa⁴, Hayamasa Yamaguchi⁴, Tomohiro Kameda² and Hiroaki Dobashi², ¹Kagawa University, Kagawa, Japan, ²Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa University, Kagawa, Japan, ³Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa University, Kidagun, Japan, ⁴Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa University, Miki-cho, Kita-gun, Japan, ⁵Kagawa University, Miki-cho, Kita-gun, Japan, ⁶Kagawa University, Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa, Japan, ⁷Kagawa University, Miki, Kita District, Kagawa, Japan
Background/Purpose: It is important to control disease activity during pregnancy in women with rheumatic diseases because its exacerbation is associated with increased adverse pregnancy outcomes.…
Abstract Number: 1684 • ACR Convergence 2023
The Impact of Pregnancy Timing on Outcomes in SLE
Catherine Sims¹, Amanda Eudy², Ceshae Harding¹, Cuoghi Edens³, Mehret Birru Talabi⁴, Rosalind Ramsey-Goldman⁵, Laura Neil¹ and Megan Clowse⁶, ¹Duke University, Durham, NC, ²Duke University, Raleigh, NC, ³University of Chicago, Chicago, IL, ⁴University of Pittsburgh, Pittsburgh, PA, ⁵Northwestern University, Chicago, IL, ⁶Duke University, Chapel Hill, NC
Background/Purpose: To minimize risk of poor pregnancy outcomes, the ACR Reproductive Health Guideline recommends women conceive when SLE is well controlled and treated with pregnancy-compatible…
Abstract Number: 0469 • ACR Convergence 2023
Hydroxychloroquine and Preeclampsia Risk in Lupus Pregnancy: Results from a Large Regional Integrated Health Network
Julia Simard¹, Emily Liu², Amadeia Rector³, Miranda Cantu⁴, Daniel Kuo⁵, Eliza Chakravarty⁶, Maurice Druzin⁷, Gary Shaw⁷, Michael Weisman⁸ and Monique Hedderson², ¹Department of Epidemiology & Population Health, Stanford University School of Medicine, Stanford, CA, ²Kaiser Permanente Division of Research, Oakland, CA, ³Stanford University, San Francisco, CA, ⁴Global Lupus Support Group, Portage, MI, ⁵Kaiser Permanente, Redwood City, CA, ⁶Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁷Stanford University, Stanford, CA, ⁸Stanford, Los Angeles, CA
Background/Purpose: Pregnancies in patients with systemic lupus erythematosus (SLE) are at greater risk of preeclampsia. Hydroxychloroquine (HCQ) is recommended during SLE pregnancy to control disease…
Abstract Number: 1348 • ACR Convergence 2023
Reproductive Outcomes for Women with Vasculitis
Catherine Sims¹, Christine Yeung², Heather Tam³, Joyce Kullman⁴, Amanda Eudy⁵, Renee Borchin⁶, Cristina Burroughs⁶, Megan Clowse⁷ and Peter Merkel², ¹Duke University School of Medicine, Durham, NC, ²University of Pennsylvania, Philadelphia, PA, ³Vasculitis Patient Powered Research Network, Stanford, CA, ⁴Vasculitis Foundation, Kansas City, MO, ⁵Duke University, Raleigh, NC, ⁶University of South Florida, Tampa, FL, ⁷Duke University, Chapel Hill, NC
Background/Purpose: There are limited data on the reproductive health of women with vasculitis. This study utilized a large, prospective, international vasculitis pregnancy registry to survey…
Abstract Number: 1824 • ACR Convergence 2023
Breakthrough COVID-19 and Severity After Vaccination Among Pregnant Persons with Rheumatic Diseases
Anna Sutton¹, Carolyn Hilliard², Qiuyuan Qin³, Alfred Jared Anzalone⁴, Mary Toth⁵, Rena Patel⁶ and Namrata Singh⁷, ¹Department of Epidemiology, University of Washington School of Public Health, Woodinville, WA, ²Department of Internal Medicine SSM Saint Louis University, St. Louis, MO, ³Department of Public Health, University of Rochester, Rochester, NY, ⁴Department of Neurological Sciences, University of Nebraska Medical Center, Omaha, NE, ⁵Nemours Foundation, Orlando, FL, ⁶Departments of Medicine and Global Health, University of Washington, Seattle, WA, ⁷University of Washington, Bellevue, WA
Background/Purpose: Acknowledgment: Contributed on behalf of the National COVID Cohort Collaborative (N3C) ConsortiumIndividuals with rheumatologic diseases (RD) are at higher risk for severe COVID-19 compared…
Abstract Number: L13 • ACR Convergence 2022
Fetal Cardiac Targets Identify the Autoantibodies Associated with Congenital Heart Block
Stephanie Benjamin¹, Lisa Vi², Diptendu Chatterjee¹, Edgar Jaeggi¹, Marie Wahren-Herlenius³, Amelia Ruffatti⁴, Linda Hiraki⁵, Michelle Lohbihler², Lusia Sepiashvili¹, Carl Laskin⁶, Meena Fatah¹, Daniela Dominguez⁵, Lawrence Ng⁵, Anthony Gramolini², Vincent Christoffels⁷, Stephanie Protze² and Robert Hamilton⁸, ¹Hospital for Sick Children, Toronto, ON, Canada, ²University of Toronto, Toronto, ON, Canada, ³Karolinska Institutet, Stockholm, Stockholms Lan, Sweden, ⁴Universitå di Padova, Padova, Italy, ⁵The Hospital for Sick Children, Toronto, ON, Canada, ⁶Mt. Sinai Hospital/University of Toronto, Toronto, ON, Canada, ⁷Amsterdam UMC, Amsterdam, Zuid-Holland, Netherlands, ⁸Hospital for Sick Children, Markham, ON, Canada
Background/Purpose: Autoimmune congenital heart block (CHB+) affects the fetus of mothers with anti-Ro antibodies. Anti-Ro (Ro+) antibodies (Abs) are usually present in maternal sera when…
Abstract Number: 0320 • ACR Convergence 2022
Metabolomics in Systemic Lupus Erythematosus and Pregnancy – A Prospective Observational Longitudinal Study
Shi-Nan Luong¹, Isabella Sheldon², Charles Raine³, Elizabeth Jury³ and Ian Giles³, ¹University College London, United Kingdom and University of New South Wales, Sydney, Australia, ²London School of Hygiene and Tropical Medicine, London, United Kingdom, ³University College London, London, United Kingdom
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disease characterised by activation of immunological and cellular pathways, disease flares and adverse pregnancy outcomes (APO). Metabolomic…
Abstract Number: 0959 • ACR Convergence 2022
Assessing the Association Between Hydroxychloroquine and Preeclampsia Risk in SLE Pregnancies Using Administrative Claims Data
Amadeia Rector¹, Ivana Marić², Yashaar Chaichian³, Eliza Chakravarty⁴, Miranda Cantu⁵, Michael Weisman⁶, Gary Shaw⁷, Maurice Druzin⁷ and Julia Simard¹, ¹Stanford University School of Medicine, Palo Alto, CA, ²Stanford University, Stanford, ³Stanford University, Stanford, CA, ⁴Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁵Global Lupus Support Group, Portage, MI, ⁶Adjunct Professor of Medicine, Stanford University; Distinguished Professor of Medicine Emeritus, David Geffen School of Medicine at UCLA, Los Angeles, CA, ⁷Stanford University School of Medicine, Palo Alto
Background/Purpose: Preeclampsia risk is higher among pregnancies in patients with systemic lupus erythematosus (SLE). Hydroxychloroquine (HCQ), a common first-line treatment, is encouraged in SLE pregnancies…
Abstract Number: 2083 • ACR Convergence 2022
A Network Meta-analysis on 532 SLE Patients: Low Complement Levels in the First Trimester Predict Disease Flare in Pregnancy
Massimo Radin¹, Irene Cecchi², Francesca Crisafulli³, Evandro Mendes Klumb⁴, Guilherme Ramires De Jesús⁴, Miguel Ángel Saavedra⁵, Geraldine Vanessa Reyes-Navarro⁶, Luca iaccarino⁷, Maddalena Larosa⁷, Gabriella Moroni⁸, Francesco Tamborini⁹, dario Roccatello¹, Laura Andreoli³, Cecilia Beatrice Chighizola¹⁰ and Savino Sciascia², ¹University of Turin, Turin, Italy, ²University of Turin, Torino, Italy, ³University of Brescia, Brescia, Italy, ⁴Instituto Fernandes Figueira, Rio De Janeiro, Brazil, ⁵Hospital de Especialidades Dr. Antonio Fraga Mouret, Ciudad de México, Mexico, ⁶Benemérita Universidad Autónoma de Puebla, Puebla, Mexico, ⁷University of Padova, Padova, Italy, ⁸Humanitas University, Rozzano, Italy, ⁹Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, Italy, ¹⁰University of Milan, Milano, Italy
Background/Purpose: The complement system is a key-player in the pathogenesis of systemic lupus erythematosus (SLE); decrease in C3 and C4 levels correlates with disease activity…

« Previous Page
1
…
5
6
7
8
9
…
19
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].